Kamada (KMDA) Set to Announce Earnings on Wednesday

Kamada (NASDAQ:KMDA) is scheduled to announce its earnings results before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. Kamada has set its FY 2024 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.04. The business had revenue of $36.43 million for the quarter, compared to analysts’ expectations of $37.71 million. Kamada had a return on equity of 5.66% and a net margin of 5.81%. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada Stock Performance

Kamada stock traded down $0.15 during trading on Tuesday, hitting $5.56. The company’s stock had a trading volume of 694 shares, compared to its average volume of 22,277. The stock’s fifty day moving average is $5.59 and its 200 day moving average is $5.50. Kamada has a 1-year low of $4.08 and a 1-year high of $6.53. The stock has a market capitalization of $319.59 million, a price-to-earnings ratio of 38.07 and a beta of 1.05.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Kamada in a research report on Thursday, March 7th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.